Please assess the completion status of the following clinical trial:

Trial Title: HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient Inclusion Criteria for Sickle Cell Disease~* Patients at least one year of age to less than or equal to 21 years of age with (Sickle Cell Disease-SS or Sickle Cell-S-β-Thalassemia and with one or more of the following disease complications:~* Development of stroke on chronic transfusion protocol.~* Allosensitization on chronic transfusion therapy~* Impaired neuropsychological function and abnormal MRI scan~* Abnormal Transcranial Doppler studies~* Acute chest syndrome (2 to 3 episodes of acute chest syndrome in last 3 to 4 years).~* Ferritin level \< 1500 mg/ml~* Recurrent painful priapism; 3-4 episodes/year requiring intervention.~* Recurrent vaso-occlusive crisis of at least 3 to 4 episodes/year.~* Osteonecrosis of multiple bones with documented destructive changes.~* Signed informed consent~* Patients physically and psychologically capable of undergoing transplantation and a period of strict isolation.~* Ferritin \< 1500~* Liver Iron Concentration \< 6mg/g~Patient Inclusion Criteria for β Thalassemia major Patients less than or equal to 21 years of age with B- Thalassemia major on routine monthly transfusion protocol or with one or more of the following complications;~1. Hepatomegaly.~2. Liver biopsy revealing evidence of portal fibrosis as A) Mild B) Moderate~3. Ferritin level≤ 1500ng/ml~4. Liver Iron Concentration (LIC) \< 6mg/g~Exclusion Criteria:~* Exclusion Criteria for Both Sickle Cell and β Thalassemia Major Patient~* HIV positive result confirmed by Western Blot.~* Pregnancy (Pregnancy testing for females of child-bearing age will be performed and those with a positive serum β-Human Chorionic Gonadotropin will be excluded) and lactating females.~* Creatinine greater than two times the upper limit of normal for the laboratory,~* Pulmonary disease with FVC, FEV1 or DLCO parameters \< 50% predicted (corrected for hemoglobin) or stage 3 or 4 sickle lung disease.~* Cardiac insufficiency or coronary artery disease requiring treatment~* Active infection requiring systemic antibiotic therapy with antibacterial, antifungal or antiviral agents~* Lansky performance score \<70%- (Appendix B)~* Acute hepatitis/biopsy evidence of cirrhosis.~* Pulmonary Hypertension

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Reduced Intensity Regimen (Type: EXPERIMENTAL): Administration of reduced doses of alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by daily dose of 10mg/dose on Day -19 to Day -17 for patients \<10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients \> 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. On Day -1 Cyclosporine OR Tacrolimus will be initiated along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. On Day 0 the Human Leukocyte Antigen (HLA) matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused.

Based on this trial design, predict the completion outcome and termination type (if applicable).